PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact


Search


PDF Archive search engine
Last database update: 14 August at 21:27 - Around 220000 files indexed.

Show results per page

Results for «tumors»:


Total: 500 results - 0.056 seconds

Global Solid Tumors Drug Sales Market 2016 98%

Global Solid Tumors Drug Sales Market 2016 Industry Trend and Forecast 2021 www.orbisresearch.com;

https://www.pdf-archive.com/2016/08/25/global-solid-tumors-drug-sales-market-2016/

25/08/2016 www.pdf-archive.com

Munson 75 97%

This report represents an effort to test various cannabinoids in several In vivo and in vitro tumor systems to determine the kinds of tumors that are sensitive to these compounds and reveal their possible biochemical sites of action(s).

https://www.pdf-archive.com/2016/01/22/munson-75/

22/01/2016 www.pdf-archive.com

ADCs for Clinical Research in the Global Market 97%

https://www.biochempeg.com Biochempeg Scientific Inc.

https://www.pdf-archive.com/2020/02/28/adcs-for-clinical-research-in-the-global-market/

28/02/2020 www.pdf-archive.com

Most commons by Yatin Talwar 96%

Most common component of mixed germ cell tumors :

https://www.pdf-archive.com/2014/05/17/most-commons-by-yatin-talwar/

17/05/2014 www.pdf-archive.com

JDIT-2014-1030-006 96%

www.openmedscience.com Review Article 68 Ga-Somatostatin Tumors Analogue PET/CT in Neuroendocrine Elisabetta Giovannini*, Maria Chiara Gaeta, Andrea Ciarmiello Nuclear Medicine Unit, Sant’Andrea Hospital, La Spezia, Italy *Author to whom correspondence should be addressed:

https://www.pdf-archive.com/2017/05/30/jdit-2014-1030-006/

30/05/2017 www.pdf-archive.com

IJEAS0404028 95%

Imaging tumors which are more accurate plays a crucial role in diagnosis of the same.

https://www.pdf-archive.com/2017/09/10/ijeas0404028/

10/09/2017 www.pdf-archive.com

IJETR2101 95%

In this research work, they used four different classes of brain tumors and extracted the GLCM based textural features of each class, and they applied to two layered Feed forward Neural Network, which gives 97.5% classification rate.

https://www.pdf-archive.com/2017/12/24/ijetr2101/

24/12/2017 www.pdf-archive.com

2017DBS Antibody Flyer 102017 web 94%

It has demonstrated utility in the differential diagnosis between these primary tumors and corresponding metastatic renal cell carcinoma within the context of an antibody panel.

https://www.pdf-archive.com/2017/10/30/2017dbs-antibody-flyer-102017-web/

30/10/2017 www.pdf-archive.com

Anorectal-Applicator 93%

Unique Device Dimensions »» 2.3 cm uninflated insertion diameter for ease of placement »» 8-10cm effective treatment zone allows treatment of entire rectum without repositioning Visible Dual Balloon Construction »» 3.5-4cm inner balloon inflated diameter creates consistent, repeatable source catheter positioning »» Outer balloon creates protective spacing between source catheters and tissue, fully distending the rectum ensuring repeatable tumor coverage Repeatable »» Radio-opaque contrast markers visible under X-ray, CT and MRI ensure consistent device placement »» Contrast Markers and handle markings ensure depth and rotational consistency »» Inner balloon design ensures precise, consistent source catheter positioning Optimal »» Consistent fill volumes ensure repeatable tissue spacing »» Compliant outer balloon ensures optimal tissue separation and conformity around tumors »» Non-compliant inner balloon supports 8 evenly spaced treatment catheters ensuring optimal positioning for surface dose control »» Device construction and materials designed to take full advantage of MRI guided brachytherapy Distributed by 490 West 84th St Hialeah, FL 33014 (844) ANCERMED • (844) 262-3763 New Horizons in Radiation Oncology www.ancermedical.com Made in USA Patents Pending MKT-0001-00- Rev 3 “The uniquely compliant design of the AR Applicator allows exophytic tumors to press closer to the source catheters than healthy tissue, resulting in the ability to deliver a very high dose to the tumor, maintaining superior dose coverage of the target volume while sparing healthy tissue.

https://www.pdf-archive.com/2016/07/12/anorectal-applicator/

12/07/2016 www.pdf-archive.com

Abstract 93%

However, despite initial response, most patients experience relapse with resistant tumors within a year.

https://www.pdf-archive.com/2017/06/13/abstract/

13/06/2017 www.pdf-archive.com

ER0884 93%

paula.nora@norahsevents.pt http://norahsevents.eventkey.pl/ 30 JUNHO 2017 EUROSTARS 0P0RT0 HOTEL - PORTO NETWORK DE TUMORES NEUROENDÓCRINOS 30 JUNHO 2017 11.30 EUROSTARS OPORTO HOTEL - PORTO Interplay between NF-KB signaling and PI3K-AKT-m TORpathwayin Gastroenteropancreatic Neuroendocrine Tumors:

https://www.pdf-archive.com/2018/01/16/er0884/

16/01/2018 www.pdf-archive.com

cv-pantel 93%

Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.

https://www.pdf-archive.com/2018/03/19/cv-pantel/

19/03/2018 www.pdf-archive.com

Bone Cancer treatment 93%

All bone tumors are not malignant.

https://www.pdf-archive.com/2018/12/25/bone-cancer-treatment/

25/12/2018 www.pdf-archive.com

2534 - MD Anderson Cancer Center Madrid- Pathology Meeting - program 92%

Houston, USA 14:15 - 15:00 Aggressive tumors of the skin appendages:

https://www.pdf-archive.com/2018/06/18/untitled-pdf-document/

18/06/2018 www.pdf-archive.com

mammograms 92%

By Emily Oster Filed under Women's Health A Canadian study published in February reignited the years-long debate over breast cancer screening methods, arguing fairly strongly against mammography, or the use of X-rays to detect tumors.

https://www.pdf-archive.com/2017/02/23/mammograms-1/

23/02/2017 www.pdf-archive.com

JDIT-2014-1007-004 91%

Women with ER-positive breast tumors have a better prognosis than women with ER-negative tumors in terms of responsiveness to anti-estrogen treatment.

https://www.pdf-archive.com/2017/05/30/jdit-2014-1007-004/

30/05/2017 www.pdf-archive.com

Weinstein & Ciszek 2002 91%

Introduction Why do we get tumors and Why do we grow old?

https://www.pdf-archive.com/2017/06/11/weinstein-ciszek-2002/

11/06/2017 www.pdf-archive.com

sample 81 82 83 91%

rarely, can cause carcinoid syndrome More common than primary tumors iv.

https://www.pdf-archive.com/2017/12/14/sample-81-82-83/

14/12/2017 www.pdf-archive.com

Boston Biomarker Poster 03192014 91%

A MULTIANALYTE ALGORITHM PCR-BASED BLOOD TEST OUTPERFORMS SINGLE ANALYTE ELISA-BASED BLOOD TESTS FOR NEUROENDOCRINE TUMOR DETECTION A key issue in management of neuroendocrine tumors (NETs) is specific and sensitive biomarkers.

https://www.pdf-archive.com/2014/03/21/boston-biomarker-poster-03192014/

21/03/2014 www.pdf-archive.com

JDIT-2016-0712-022 91%

Because of the excellent outcome of DTC and the potential cancerous effect of iodine-131, in the last years there has been a huge number of articles addressing the issue of the incidence of second tumors in DTC patients.

https://www.pdf-archive.com/2017/05/30/jdit-2016-0712-022/

30/05/2017 www.pdf-archive.com

cyberknife treatment for cancers1092 90%

In order to treat both cancerous and noncancerous tumors which are present anywhere in the body, the CyberKnife Robotic Radiosurgery System is a non-invasive alternative for surgery.

https://www.pdf-archive.com/2013/11/05/cyberknife-treatment-for-cancers1092/

05/11/2013 www.pdf-archive.com

An Overview of Basal Cell Carcinoma 90%

Tumors appear most frequently on sun-exposed surfaces of the body (Sarma et al.

https://www.pdf-archive.com/2013/02/24/an-overview-of-basal-cell-carcinoma/

24/02/2013 www.pdf-archive.com